REGN logo

REGN Shareholders equity

annual shareholders equity:

$29.35B+$3.38B(+13.02%)
December 31, 2024

Summary

  • As of today (May 29, 2025), REGN annual stockholders equity is $29.35 billion, with the most recent change of +$3.38 billion (+13.02%) on December 31, 2024.
  • During the last 3 years, REGN annual shareholders equity has risen by +$10.58 billion (+56.40%).
  • REGN annual shareholders equity is now at all-time high.

Performance

REGN Shareholders equity Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNbalance sheet metrics

quarterly shareholders equity:

$29.39B+$34.00M(+0.12%)
March 31, 2025

Summary

  • As of today (May 29, 2025), REGN quarterly stockholders equity is $29.39 billion, with the most recent change of +$34.00 million (+0.12%) on March 31, 2025.
  • Over the past year, REGN quarterly shareholders equity has increased by +$2.40 billion (+8.88%).
  • REGN quarterly shareholders equity is now at all-time high.

Performance

REGN quarterly shareholders equity Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNbalance sheet metrics

Shareholders equity Formula

Shareholders Equity = Total Assets − Total Liabilities

REGN Shareholders equity Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+13.0%+8.9%
3 y3 years+56.4%+47.6%
5 y5 years+164.7%+142.2%

REGN Shareholders equity Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+56.4%at high+47.6%
5 y5-yearat high+166.2%at high+224.5%
alltimeall timeat high>+9999.0%at high>+9999.0%

REGN Shareholders equity History

DateAnnualQuarterly
Mar 2025
-
$29.39B(+0.1%)
Dec 2024
$29.35B(+13.0%)
$29.35B(+0.1%)
Sep 2024
-
$29.33B(+4.0%)
Jun 2024
-
$28.21B(+4.5%)
Mar 2024
-
$26.99B(+3.9%)
Dec 2023
$25.97B(+14.6%)
$25.97B(+4.3%)
Sep 2023
-
$24.90B(+3.7%)
Jun 2023
-
$24.02B(+2.2%)
Mar 2023
-
$23.50B(+3.7%)
Dec 2022
$22.66B(+20.8%)
$22.66B(+5.7%)
Sep 2022
-
$21.44B(+3.6%)
Jun 2022
-
$20.69B(+3.9%)
Mar 2022
-
$19.91B(+6.1%)
Dec 2021
$18.77B(+70.2%)
$18.77B(+8.8%)
Sep 2021
-
$17.26B(+14.1%)
Jun 2021
-
$15.13B(+26.3%)
Mar 2021
-
$11.98B(+8.6%)
Dec 2020
$11.03B(-0.6%)
$11.03B(+8.9%)
Sep 2020
-
$10.13B(+11.8%)
Jun 2020
-
$9.06B(-25.3%)
Mar 2020
-
$12.13B(+9.4%)
Dec 2019
$11.09B(+26.6%)
$11.09B(+5.6%)
Sep 2019
-
$10.50B(+7.7%)
Jun 2019
-
$9.76B(+3.3%)
Mar 2019
-
$9.44B(+7.8%)
Dec 2018
$8.76B(+42.5%)
$8.76B(+11.3%)
Sep 2018
-
$7.87B(+9.5%)
Jun 2018
-
$7.19B(+9.4%)
Mar 2018
-
$6.57B(+6.9%)
Dec 2017
$6.14B(+38.1%)
$6.14B(+1.5%)
Sep 2017
-
$6.05B(+9.6%)
Jun 2017
-
$5.52B(+13.5%)
Mar 2017
-
$4.87B(+9.4%)
Dec 2016
$4.45B(+21.7%)
$4.45B(-0.9%)
Sep 2016
-
$4.49B(+10.2%)
Jun 2016
-
$4.08B(+8.3%)
Mar 2016
-
$3.77B(+3.0%)
Dec 2015
$3.65B(+43.3%)
$3.65B(+10.9%)
Sep 2015
-
$3.30B(-1.2%)
Jun 2015
-
$3.34B(+12.4%)
Mar 2015
-
$2.97B(+16.5%)
Dec 2014
$2.55B(+30.6%)
$2.55B(-0.1%)
Sep 2014
-
$2.55B(+7.7%)
Jun 2014
-
$2.37B(+7.1%)
Mar 2014
-
$2.21B(+13.3%)
Dec 2013
$1.95B(+56.7%)
$1.95B(+15.5%)
Sep 2013
-
$1.69B(+13.2%)
Jun 2013
-
$1.49B(+6.2%)
Mar 2013
-
$1.41B(+12.9%)
Dec 2012
$1.25B(+156.4%)
$1.25B(+54.5%)
Sep 2012
-
$806.02M(+35.5%)
Jun 2012
-
$594.66M(+18.0%)
Mar 2012
-
$504.02M(+3.8%)
Dec 2011
$485.73M(-8.0%)
$485.73M(+13.4%)
Sep 2011
-
$428.25M(-10.4%)
Jun 2011
-
$478.03M(-7.7%)
Mar 2011
-
$518.09M(-1.8%)
Dec 2010
$527.82M(+33.0%)
$527.82M(+51.6%)
Sep 2010
-
$348.06M(-6.2%)
Jun 2010
-
$371.22M(-3.9%)
Mar 2010
-
$386.27M(-2.6%)
Dec 2009
$396.76M(-5.9%)
$396.76M(-6.1%)
Sep 2009
-
$422.44M(+2.9%)
Jun 2009
-
$410.51M(+0.0%)
Mar 2009
-
$410.32M(-2.7%)
Dec 2008
$421.51M
$421.51M(-3.5%)
Sep 2008
-
$436.93M(-3.1%)
Jun 2008
-
$451.00M(-2.1%)
DateAnnualQuarterly
Mar 2008
-
$460.60M(+0.1%)
Dec 2007
$460.27M(+112.5%)
$460.27M(+204.0%)
Sep 2007
-
$151.40M(-15.6%)
Jun 2007
-
$179.34M(-8.8%)
Mar 2007
-
$196.69M(-9.2%)
Dec 2006
$216.62M(+90.0%)
$216.62M(+246.7%)
Sep 2006
-
$62.47M(-25.4%)
Jun 2006
-
$83.77M(-18.1%)
Mar 2006
-
$102.32M(-10.2%)
Dec 2005
$114.00M(-37.5%)
$114.00M(-16.4%)
Sep 2005
-
$136.38M(-17.4%)
Jun 2005
-
$165.06M(-11.2%)
Mar 2005
-
$185.78M(+1.8%)
Dec 2004
$182.54M(+32.6%)
$182.54M(+2.1%)
Sep 2004
-
$178.87M(-5.9%)
Jun 2004
-
$190.13M(-6.8%)
Mar 2004
-
$204.11M(+48.3%)
Dec 2003
$137.64M(-5.7%)
$137.64M(-11.9%)
Sep 2003
-
$156.20M(+13.3%)
Jun 2003
-
$137.84M(-16.8%)
Mar 2003
-
$165.62M(+13.4%)
Dec 2002
$145.98M(-45.2%)
$145.98M(-19.3%)
Sep 2002
-
$180.79M(-15.2%)
Jun 2002
-
$213.16M(-12.1%)
Mar 2002
-
$242.48M(-9.0%)
Dec 2001
$266.36M(+46.2%)
$266.36M(-9.7%)
Sep 2001
-
$294.87M(-5.9%)
Jun 2001
-
$313.29M(-3.4%)
Mar 2001
-
$324.41M(+78.1%)
Dec 2000
$182.13M(+66.3%)
$182.13M(-4.6%)
Sep 2000
-
$190.97M(+8.5%)
Jun 2000
-
$175.97M(+66.6%)
Mar 2000
-
$105.59M(-3.6%)
Dec 1999
$109.50M(-16.5%)
$109.50M(-0.9%)
Sep 1999
-
$110.50M(-4.2%)
Jun 1999
-
$115.40M(-6.5%)
Mar 1999
-
$123.40M(-5.9%)
Dec 1998
$131.20M(-5.5%)
$131.20M(-4.2%)
Sep 1998
-
$136.90M(-0.7%)
Jun 1998
-
$137.80M(+1.8%)
Mar 1998
-
$135.40M(-2.5%)
Dec 1997
$138.90M(+29.9%)
$138.90M(+0.5%)
Sep 1997
-
$138.20M(-1.2%)
Jun 1997
-
$139.90M(+38.5%)
Mar 1997
-
$101.00M(-5.5%)
Dec 1996
$106.90M(+57.4%)
$106.90M(+2.6%)
Sep 1996
-
$104.20M(-7.6%)
Jun 1996
-
$112.80M(+81.6%)
Mar 1996
-
$62.10M(-8.5%)
Dec 1995
$67.90M(+1.2%)
$67.90M(+28.1%)
Sep 1995
-
$53.00M(-10.8%)
Jun 1995
-
$59.40M(-6.9%)
Mar 1995
-
$63.80M(-4.9%)
Dec 1994
$67.10M(-31.8%)
$67.10M(-7.8%)
Sep 1994
-
$72.80M(-5.0%)
Jun 1994
-
$76.60M(-11.6%)
Mar 1994
-
$86.70M(-11.9%)
Dec 1993
$98.40M(+12.8%)
$98.40M(-10.6%)
Sep 1993
-
$110.10M(+61.0%)
Jun 1993
-
$68.40M(-12.1%)
Mar 1993
-
$77.80M(-10.8%)
Dec 1992
$87.20M(-17.9%)
$87.20M(-6.7%)
Sep 1992
-
$93.50M(-5.8%)
Jun 1992
-
$99.30M(-3.6%)
Mar 1992
-
$103.00M(-3.0%)
Dec 1991
$106.20M(+770.5%)
$106.20M(-2.0%)
Sep 1991
-
$108.40M(-0.8%)
Jun 1991
-
$109.30M(+795.9%)
Dec 1990
$12.20M
$12.20M

FAQ

  • What is Regeneron Pharmaceuticals annual stockholders equity?
  • What is the all time high annual shareholders equity for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals annual shareholders equity year-on-year change?
  • What is Regeneron Pharmaceuticals quarterly stockholders equity?
  • What is the all time high quarterly shareholders equity for Regeneron Pharmaceuticals?
  • What is Regeneron Pharmaceuticals quarterly shareholders equity year-on-year change?

What is Regeneron Pharmaceuticals annual stockholders equity?

The current annual shareholders equity of REGN is $29.35B

What is the all time high annual shareholders equity for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high annual stockholders equity is $29.35B

What is Regeneron Pharmaceuticals annual shareholders equity year-on-year change?

Over the past year, REGN annual stockholders equity has changed by +$3.38B (+13.02%)

What is Regeneron Pharmaceuticals quarterly stockholders equity?

The current quarterly shareholders equity of REGN is $29.39B

What is the all time high quarterly shareholders equity for Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals all-time high quarterly stockholders equity is $29.39B

What is Regeneron Pharmaceuticals quarterly shareholders equity year-on-year change?

Over the past year, REGN quarterly stockholders equity has changed by +$2.40B (+8.88%)
On this page